Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Vincent Louie Ramos Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11668–11670.

https://doi.org/10.1182/blood-2022-167512

Published: 2022

Journal Articles

Superior Outcomes in Hispanic Patients Compared to Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen for Newly Diagnosed ALL Patients in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2021-150116

Published: 2021

Journal Articles

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2021-150135

Published: 2021